vs
Side-by-side financial comparison of Citi Trends Inc (CTRN) and Guardant Health, Inc. (GH). Click either name above to swap in a different company.
Guardant Health, Inc. is the larger business by last-quarter revenue ($281.3M vs $197.1M, roughly 1.4× Citi Trends Inc). Citi Trends Inc runs the higher net margin — -3.5% vs -45.7%, a 42.2% gap on every dollar of revenue. On growth, Guardant Health, Inc. posted the faster year-over-year revenue change (39.4% vs 10.1%). Citi Trends Inc produced more free cash flow last quarter ($767.0K vs $-54.2M). Over the past eight quarters, Guardant Health, Inc.'s revenue compounded faster (29.2% CAGR vs -4.3%).
Citi Trends, Inc. is an American retail clothing chain selling discounted products targeted primarily at African-American customers.
Guardant Health, Inc. is an American biotechnology company based in Palo Alto, California. Co-founders Helmy Eltoukhy and AmirAli Talasaz serve as co-chief executive officers.
CTRN vs GH — Head-to-Head
Income Statement — Q3 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $197.1M | $281.3M |
| Net Profit | $-6.9M | $-128.5M |
| Gross Margin | — | 64.6% |
| Operating Margin | -3.7% | -43.0% |
| Net Margin | -3.5% | -45.7% |
| Revenue YoY | 10.1% | 39.4% |
| Net Profit YoY | 3.6% | -15.8% |
| EPS (diluted) | $-0.86 | $-1.01 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $197.1M | $281.3M | ||
| Q3 25 | $190.8M | $265.2M | ||
| Q2 25 | $201.7M | $232.1M | ||
| Q1 25 | $211.2M | $203.5M | ||
| Q4 24 | $179.1M | $201.8M | ||
| Q3 24 | $176.6M | $191.5M | ||
| Q2 24 | $186.3M | $177.2M | ||
| Q1 24 | $215.2M | $168.5M |
| Q4 25 | $-6.9M | $-128.5M | ||
| Q3 25 | $3.8M | $-92.7M | ||
| Q2 25 | $871.0K | $-99.9M | ||
| Q1 25 | $-14.2M | $-95.2M | ||
| Q4 24 | $-7.2M | $-111.0M | ||
| Q3 24 | $-18.4M | $-107.8M | ||
| Q2 24 | $-3.4M | $-102.6M | ||
| Q1 24 | $3.6M | $-115.0M |
| Q4 25 | — | 64.6% | ||
| Q3 25 | — | 64.7% | ||
| Q2 25 | — | 65.0% | ||
| Q1 25 | — | 63.3% | ||
| Q4 24 | — | 61.6% | ||
| Q3 24 | — | 61.1% | ||
| Q2 24 | — | 59.1% | ||
| Q1 24 | — | 61.2% |
| Q4 25 | -3.7% | -43.0% | ||
| Q3 25 | 1.8% | -37.3% | ||
| Q2 25 | 0.2% | -45.9% | ||
| Q1 25 | 0.6% | -54.6% | ||
| Q4 24 | -4.9% | -62.4% | ||
| Q3 24 | -14.1% | -61.3% | ||
| Q2 24 | -3.7% | -56.8% | ||
| Q1 24 | 1.8% | -59.2% |
| Q4 25 | -3.5% | -45.7% | ||
| Q3 25 | 2.0% | -35.0% | ||
| Q2 25 | 0.4% | -43.0% | ||
| Q1 25 | -6.7% | -46.8% | ||
| Q4 24 | -4.0% | -55.0% | ||
| Q3 24 | -10.4% | -56.3% | ||
| Q2 24 | -1.8% | -57.9% | ||
| Q1 24 | 1.7% | -68.2% |
| Q4 25 | $-0.86 | $-1.01 | ||
| Q3 25 | $0.46 | $-0.74 | ||
| Q2 25 | $0.11 | $-0.80 | ||
| Q1 25 | $-1.70 | $-0.77 | ||
| Q4 24 | $-0.86 | $-0.90 | ||
| Q3 24 | $-2.21 | $-0.88 | ||
| Q2 24 | $-0.42 | $-0.84 | ||
| Q1 24 | $0.43 | $-0.94 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $378.2M |
| Total DebtLower is stronger | — | $1.5B |
| Stockholders' EquityBook value | $107.8M | $-99.3M |
| Total Assets | $464.3M | $2.0B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $378.2M | ||
| Q3 25 | — | $580.0M | ||
| Q2 25 | — | $629.1M | ||
| Q1 25 | — | $698.6M | ||
| Q4 24 | — | $525.5M | ||
| Q3 24 | — | $585.0M | ||
| Q2 24 | — | $933.7M | ||
| Q1 24 | — | $1.0B |
| Q4 25 | — | $1.5B | ||
| Q3 25 | — | $1.1B | ||
| Q2 25 | — | $1.1B | ||
| Q1 25 | — | $1.1B | ||
| Q4 24 | — | $1.1B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $107.8M | $-99.3M | ||
| Q3 25 | $113.2M | $-354.5M | ||
| Q2 25 | $108.6M | $-305.5M | ||
| Q1 25 | $113.2M | $-250.8M | ||
| Q4 24 | $130.3M | $-139.6M | ||
| Q3 24 | $136.6M | $-60.1M | ||
| Q2 24 | $154.8M | $-1.6M | ||
| Q1 24 | $157.7M | $68.3M |
| Q4 25 | $464.3M | $2.0B | ||
| Q3 25 | $457.4M | $1.3B | ||
| Q2 25 | $437.4M | $1.3B | ||
| Q1 25 | $462.8M | $1.3B | ||
| Q4 24 | $467.1M | $1.5B | ||
| Q3 24 | $506.7M | $1.5B | ||
| Q2 24 | $484.1M | $1.6B | ||
| Q1 24 | $518.7M | $1.7B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $8.6M | $-26.4M |
| Free Cash FlowOCF − Capex | $767.0K | $-54.2M |
| FCF MarginFCF / Revenue | 0.4% | -19.3% |
| Capex IntensityCapex / Revenue | 4.0% | 9.9% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $11.9M | $-233.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $8.6M | $-26.4M | ||
| Q3 25 | $3.9M | $-35.4M | ||
| Q2 25 | $-11.0M | $-60.3M | ||
| Q1 25 | $28.5M | $-62.7M | ||
| Q4 24 | $-18.4M | $-64.5M | ||
| Q3 24 | $5.6M | $-51.1M | ||
| Q2 24 | $-19.6M | $-94.0M | ||
| Q1 24 | $23.3M | $-30.3M |
| Q4 25 | $767.0K | $-54.2M | ||
| Q3 25 | $-1.7M | $-45.8M | ||
| Q2 25 | $-13.1M | $-65.9M | ||
| Q1 25 | $26.0M | $-67.1M | ||
| Q4 24 | $-20.4M | $-83.4M | ||
| Q3 24 | $1.7M | $-55.3M | ||
| Q2 24 | $-21.2M | $-99.1M | ||
| Q1 24 | $20.0M | $-37.2M |
| Q4 25 | 0.4% | -19.3% | ||
| Q3 25 | -0.9% | -17.3% | ||
| Q2 25 | -6.5% | -28.4% | ||
| Q1 25 | 12.3% | -33.0% | ||
| Q4 24 | -11.4% | -41.3% | ||
| Q3 24 | 0.9% | -28.9% | ||
| Q2 24 | -11.4% | -55.9% | ||
| Q1 24 | 9.3% | -22.1% |
| Q4 25 | 4.0% | 9.9% | ||
| Q3 25 | 2.9% | 3.9% | ||
| Q2 25 | 1.0% | 2.4% | ||
| Q1 25 | 1.2% | 2.2% | ||
| Q4 24 | 1.1% | 9.4% | ||
| Q3 24 | 2.2% | 2.2% | ||
| Q2 24 | 0.9% | 2.9% | ||
| Q1 24 | 1.5% | 4.1% |
| Q4 25 | — | — | ||
| Q3 25 | 1.01× | — | ||
| Q2 25 | -12.59× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 6.56× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CTRN
Segment breakdown not available.
GH
| Oncology | $189.9M | 68% |
| Biopharma Data | $54.0M | 19% |
| Screening | $35.1M | 12% |
| Licensing Other | $2.2M | 1% |
